5-Hydroxytryptamine type 2 antagonists are used to treat symptomatic
peripheral arterial disease. However, it remains unknown as to whether the administration of
sarpogrelate, a
5-hydroxytryptamine type 2 antagonist, improves the prognosis after endovascular
therapy for
critical limb ischemia (CLI). We performed a retrospective analysis using a database of 386 Japanese patients undergoing endovascular
therapy for CLI. Sixty-seven patients were treated with
sarpogrelate, and we compared their prognosis with that of an equal number of background-matched controls extracted from the population. The primary end point was the first event of either major
amputation or death from any cause, and
amputation-free survival was evaluated. The follow-up period was 21 ± 18 months (mean ± standard deviation), and 58 end points were observed. Patients treated with
sarpogrelate had a significantly higher
amputation-free survival rate than their matched controls (P = 0.036). The hazard ratio for the end point and its 95 % confidence interval was 0.57 (0.34-0.97). These results suggest that
sarpogrelate treatment is associated with a favorable prognostic outcome in CLI patients undergoing endovascular
therapy. Future prospective studies are required to investigate whether
sarpogrelate treatment would improve the prognosis of CLI patients.